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Abstract
Objective: Salmon calcitonin has chondroprotective effect both in vitro and in vivo, and is therefore being tested as
a candidate drug for cartilage degenerative diseases. Recent studies have indicated that different chondrocyte phenotypes
may express the calcitonin receptor (CTR) differentially. We tested for the presence of the CTR in chondrocytes from tri-
iodothyronin (T3)-induced bovine articular cartilage explants. Moreover, investigated the effects of human and salmon
calcitonin on the explants.
Methods: Early chondrocyte hypertrophy was induced in bovine articular cartilage explants by stimulation over four days
with 20 ng/mL T3. The degree of hypertrophy was investigated by molecular markers of hypertrophy (ALP, IHH, COLX and
MMP13), by biochemical markers of cartilage turnover (C2M, P2NP and AGNxII) and histology. The expression of the CTR
was detected by qPCR and immunohistochemistry. T3-induced explants were treated with salmon or human calcitonin.
Calcitonin down-stream signaling was measured by levels of cAMP, and by the molecular markers.
Results: Compared with untreated control explants, T3 induction increased expression of the hypertrophic markers
(p,0.05), of cartilage turnover (p,0.05), and of CTR (p,0.01). Salmon, but not human, calcitonin induced cAMP release
(p,0.001). Salmon calcitonin also inhibited expression of markers of hypertrophy and cartilage turnover (p,0.05).
Conclusions: T3 induced early hypertrophy of chondrocytes, which showed an elevated expression of the CTR and was thus
a target for salmon calcitonin. Molecular marker levels indicated salmon, but not human, calcitonin protected the cartilage
from hypertrophy. These results confirm that salmon calcitonin is able to modulate the CTR and thus have
chondroprotective effects.
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Introduction
The pathogenesis of cartilage loss in joint degenerative
diseases is not fully understood, but experimental and clinical
studies have shown that abnormal subchondral bone turnover
and cartilage calcification affects the integrity of the articular
cartilage structure [1–3]. In particular, hypertrophic differenti-
ation of chondrocytes, leading to cartilage calcification, is a key
event of the deep layer of the cartilage in early joint
deterioration [4–5]. Because of the strong inter-relationship
between cartilage and subchondral bone, an ideal agent for
joint degenerative diseases would have positive effects on both
remodeling subchondral bone and the prevention or regener-
ation of articular cartilage. However, few drugs are available to
effectively prevent or treat cartilage degradation [6].
Calcitonin is a part of the calcitonin family consisting of
calcitonin (CT), a-calcitonin gene-related peptide (a-CGRP),
bCGRP, adrenomodullin (AM), and amylin [7]. In mammals,
these peptides signal through two closely related type II GPCRs
(Calcitonin Receptor and Calcitonin Receptor-like Receptor) and
three unique receptor activity-modifying proteins (RAMPs) [8].
The combination of receptor and RAMP determines the
sensitivity of the receptor towards stimulation with the individual
ligands, i.e. the CTR with no RAMP binds human CT strongly,
while the CTR in the presence of RAMP1 is a receptor for AMY
[9]. Human CT, salmon CT, and amylin share receptors [10];
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intrinsic ability to bind to and activate the CTR in the presence of
RAMPs, most notably in the confirmation normally activated
potently by Amylin [11–12].
The literature contains some controversies on calcitonin re-
ceptor (CTR) expression in chondrocytes [13–15]. This may, for
the major part, be due to the different in vitro and ex vivo system
applied; Lin et al. [15] used primary cultured chondrocytes,
whereas Sondergaard et al. [14] used freshly isolated OA
chondrocytes. Both systems have its limitations. Segovia-Silvestre
et al. [13] showed that primary chondrocytes expressed the CTR,
both transcriptionally and translationally. Furthermore, it was
shown that the CTR could be found in OA cartilage tissue sections
in situ.
Calcitonin is widely used as an anti-resorptive agent for the
treatment of osteoporosis [16–17]. The potential use of calcitonin
in the treatment of joint degenerative diseases is being investigated
both pre-clinically and clinically. It has been found that calcitonin
has a chondroprotective effect in vitro [18;19] as it inhibits matrix
metalloproteinase (MMP) expression in articular cartilage, and
prevents net loss of collagen, hyaluronan and proteoglycan
aggregated from cartilage. Calcitonin has also been shown to
promote growth of endochondral cartilage and maturation of
growth plate cartilage [20–21]. Treatment with calcitonin has
been shown to protect against bone loss and reduce osteoarthritis
(OA) lesions in cartilage in vivo; suggesting that prevention of
subchondral bone loss contributes to protection of cartilage
integrity [22–24]. The effect of calcitonin on hypertrophic
articular cartilage is yet to be investigated.
Many of the signaling pathways identified in endochondral
ossification are also believed to be important in OA progression
through regulation of chondrocyte hypertrophy [25–28]. Bone
morphogenic protein (BMP) signaling, fibroblast growth factor
(FGF) signaling and systemic factors like thyroid hormone together
with a negative feedback loop like IHH/PTHrP are the main
regulatory pathways of growth plate chondrocyte proliferation and
hypertrophy in endochondral ossification [29–30]. BMP2 is
suggested to be a strong mediator of chondrocyte hypertrophy,
which is characterized by increased type X collagen (COLX) and
alkaline phosphatase (ALP) expression, as well as up-regulation of
Indian hedgehog expression (IHH) [31–32]. In contrast, basic
FGF (bFGF) has been shown to inhibit hypertrophy by down-
regulating IHH expression secreted by pre-hypertrophic chon-
drocytes [29;33]. Numerous evidence has confirmed the effect of
tri-iodothyronine (T3) on terminal differentiation of chondrocytes
[29;34–36]. These factors affect chondrocyte behavior in together
with locally secreted IHH and PTHrP. In addition, ascorbic acid
combined with b-glycerophosphate show a potency to induce
chondrocyte hypertrophy [37]. Nevertheless, the mechanisms of
these signaling pathways or factors modulating chondrocyte
hypertrophy in the pathogenesis of OA still need to be elucidated.
We recently presented that T3 could induce chondrocyte
hypertrophy in a full-depth cartilage explants model more
effectively than bone morphogenic protein 2 (BMP2) and basic
fibroblast growth factor (bFGF). We found that treatment for 4
days with T3 induced a pre-hypertrophic and proliferative
phenotype in articular cartilage explants, whereas treatment for
8 or more induced a calcificatious and apoptotic phenotype. The
characterization was performed by monitoring the expression
pattern of common hypertrophic [31–32] and degenerative
biomarkers [38–40]. In the present study we tested the hypothesis
that a hypertrophic cartilage phenotype would express more CTR
and thus respond to calcitonin.
Materials and Methods
Reagents
Most of the reagents were obtained from Sigma-Aldrich
(Denmark), including: phosphate buffered saline (PBS), T3,
collagenase and alkaline phosphatase assay reagents. Pronase
was bought from Roche (UK). Tumor necrosis factor a (TNF-a)
was obtained from R&D Systems (UK). Dulbecco’s Modified
Eagle Medium, Nutrient Mixture F-12 (DMEM:F12) was
purchased from Invitrogen (Denmark). Antibiotics were obtained
from Life Technologies (Denmark).
Full-depth Cartilage Explants Culture
Bovine full-depth cartilage (FDC) explants were harvested from
the proximal femoral condyle of the hind leg of cows aged #1.5-
years, retrieved from e local butchery 1–2 days after killing (Harald
Hansen, Slangerup, Denmark). A skin punch biopsy (Miltex,
Germany) 3 mm in diameter was used to take full depth cartilage
plugs (i.e. explants). The isolated explants weighing 20,30 mg
were washed three times in sterile PBS and cultured 24 hours with
DMEM:F12 with antibiotic, without serum, in 96-well plates at
37uCi n5 %C O 2. To induce chondrocyte hypertrophy, 20 ng/mL
T3 was added to the explants and incubated for 4 days. Two
calcitonin stimulation experiments were performed: i) Co-stimu-
lation with 1 nM or 10 nM salmon calcitonin (Bachem, Germany)
during the entire 4-day culture period. Explants cultured in
DMEM:F12 with antibiotics with T3 were used as controls (W/
O). At the end of experiment, the plugs were used for either
histology or RNA isolation. ii) Induction of the CTR on day 4 or 8
(by two-hour stimulation with either 10 nM human or salmon
calcitonin. For all experimenters the culture medium was changed
three times a week and the collected supernatants were stored at -
20uC for further analysis.
Cell Viability
AlamarblueH (Invitrogen, US) was used as a non-toxic reagent
for measuring cell viability and metabolic activity after the
preincubation period. After removal of the medium, a 10%
Alamarblue reagent in 10 mM PBS was added as 200 ml/well in
a 96-well plate and incubated with explants for two hours at 37uC
in 5% CO2. Then 160 ml was transferred to black microtiter plates
and the fluorescence was read at 540 nm excitation 590 nm
emission wavelength. The readout was normalized to the size of
each explant (in mg). The remaining 40 ml was discarded and the
explants were washed three times in culture medium.
Histological Analysis
Toluidine Blue staining. Cultured bovine FDC explants
were isolated at each time point and snap-frozen in liquid
nitrogen. Frozen sections (5 mm) were mounted on superfrost
+
slides, fixed in ice-cold acetone, and stained with Toluidine Blue.
Digital histographs were taken with an Olympus BX60 micro-
scope and an Olympus C5050-zoom camera. Perimeter measure-
ment was done from 20X pictures using a free-ware program for
measuring pixels.
Immunohistochemical detection of the CTR. The cul-
tured bovine FDC explants were fixed in 4% formaldehyde
(Lillie’s fluid, Sigma-Aldrich, Denmark) for 24 hours at RT. Fixed
FDC explants were embedded in paraffin and cut into 5 mm
sections for immunostaining. Immunostaining (IHC) was carried
out using 200 ng/mL monoclonal antibody, MAb-9B4-Epitope-4,
recognizing the N-terminal, extracellular domain end of the CTR
(Welcome Receptor, Australia) [41]. After deparaffinization and
rehydration, sections were demasked with citrate buffer, pH 6.0,
Effect of Salmon Calcitonin on Cartilage
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e40081and overnight incubation at 60uC. Unspecific protein binding was
blocked with 0.5% casein in TBS buffer for 20 min at RT,
followed by washing and the addition of primary antibody, mouse
IgG (isotype control, Dako, Denmark) or incubation buffer alone
(TBS). Immunoreactivity was detected using the Envision anti-
mouse HRP system (Dako, Denmark) with diaminobenzidine
(DAB, Dako, Denmark) as the chromogen. Sections were counter-
stained with Mayer’s acidic hematoxylin for 12sec, rinsed and
mounted. Digital histographs were taken using an Olympus BX60
microscope and Olympus C5050-zoom camera.
Biochemical Markers of Cartilage Turnover
All the biochemical markers were measured in the conditioned
mediuminwhichtheFDCexplantswerecultured.ReleasedMMP-
derived aggrecan degradation fragments were measured by the
AGNxII(aka.342-G2)assay(NordicBioscience,Herlev,Denmark),
which is a sandwich ELISA using the monoclonal antibody AF28
specific for the MMP-cleavage site
342FFGV, and 2C10 specific for
the G1 domain, as a biotinylated catcher and a peroxidase-labeled
detector, respectively [39;40]. Type II collagen degradation was
measuredbythecompetitiveELISAassayC2M(NordicBioscience,
Herlev, Denmark) that applies the peroxidase-labeled NB44-3C1
monoclonal antibody, specific for the MMP cleavage site
RDGAAG
872 of type II collagen [38]. Both the C2M and the
AGNxII followed the procedure described in previous publication
by our lab. Type II collagen formation was assessed by the P2NP
ELISA (Nordic Bioscience, Denmark), which utilizes a monoclonal
antibody NB208-2F8 against the EPIKG internal epitope in the N-
terminaltypeIIpro-collagendomain.Thespecificityoftheantibody
was tested with nonsense and missense peptides. Sensitivity was
tested using samples with high amount of type II collagen
propeptides supernatants from IGF-1 stimulated cartilage explants
[42], human amniotic fluid (Sunny Lab, Sittingbourne, UK) and
fetal calf serum (Sigma-Aldrich) (unpublished). Amniotic fluid was
bought from Sunnylab, a UK based company. Sunnylab has
retrieved all the necessary inform consent according to demands of
the US authorities. The samples were anonymized by Sunnylab
before dispatchment. Fetal calf serum was bought from Life
technologies. Following statement is given by the manufacture:
‘‘We manufacture FBS in compliance with the Food and Drug
Administration’s (FDA) Quality System Regulation (cGMP) at our
ISO-9001 certified facility in Grand Island, New York. In our U.S.
and New Zealand facilities, we process raw FBS under the controls
and conditionsfor the manufacture ofmedical devicesasdefined by
the FDA. Comprehensive documentation ensures traceability and
control of the process.’’
Streptavidin-coated micro-titer plates (Roche Diagnostics,
Germany) were coated with 1.25 ng/mL biotinylated EPIKG
peptide and incubated for 30 min at 20uC before being washed
five times in PBST buffer. Meanwhile, a two-fold calibration curve
was prepared starting from 2000 ng/mL free EPIKG peptide.
20 mL of conditioned medium and calibrators was added to the
plate and then 100 mL peroxidase-labeled NB208-2F8 antibody
[20 ng/mL]. After 90 min incubation at 4uC, the plate was
washed before 100 ul 3,39,5,59-tetramethylbenzidine (TMB sub-
strate, Kem-En-Tec, Denmark) was added and the plate incubated
for 15 min at 20uC. The color reactions were stopped with sulfuric
acid and read at 450 nm on a standard plate reader. The readings
were read from the 4-parameter calibrator curve.
Measurements of Alkaline Phophatase Activity
Alkaline phosphatase activity was measured in the conditioned
medium after ended culturing by a modification of the method of
Bessey et al. using p-nitrophenyl phosphate (pNP) as the substrate.
20 ml sample or standard (recombinant alkaline phosphatase) by
80 ml substrate mixture (1% 2-amino-2-methyl-1-propanol,
10.1 mM pNPP, 18 mM MgCl2, pH 10) was added to a microtiter
plate, and incubated for 20 minutes in the dark at RT. The
hydrolysis of pNP to p-nitrophenol (PnP) was stopped by adding
100 ml 0.5 M NaOH to the solution. The color change was
monitored at 405 nm on a standard plate reader.
RNA Purification
Four independent experiments were done with three replicates
per treatment. Each replicate represent a pool of five plugs from
the same cow. Due to difficulties in obtaining RNA from cartilage
tissue, an indirect method of enzymatic digestion was used to
isolate chondrocytes for their RNA. Chondrocytes were isolated
from the extracellular matrix first by adding 1.4 mg/mL pronase
E and leaving the material for 1 hr, and then 1.5 mg/mL
collagenase was added and incubated for 5–6 hrs at 37uC.
Chondrocytes were harvested by centrifuge at 250 g for 5 min.
The purification of total RNA from chondrocytes was carried out
using Absolutely RNA Miniprep Kit (Stratagene, US). RNA
integrity, quality and quantity were assessed using an Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The
RNA was either used immediately or stored at 280uC.
Quantitative Polymerase Chain Reaction
200 ng of total RNA from each of the replicates was used for
cDNA synthesis using the SuperScript
TM First-Strand Synthesis
System for RT-PCR kit (Invitrogen, US). Subsequently, the
following molecular markers of hypertrophic chondrocytes were
measured by real-time quantitative polymerase chain reaction
(qPCR): type X collagen (COL10A1), alkaline phosphatase (ALP),
Indian hedgehog (IHH), and MMP13. QPCR was also used to
measure expression level of CTR. Primer sequences are given in
table 1. The qPCR was performed using SYBR Green Supermix
(Agilent, US). Reactions were processed with 5 ul of cDNA
samples in 25 ul final volume. All PCRs stopped after 40 cycles
followed by denaturation at 95uC for 10 min. Each cycle
contained annealing for 30 seconds at 56uC for measurement of
GAPDH, at 53uC for ALP and MMP13, at 51uC for IHH and
COL10A1; extension at 72uC for 30 seconds for all reactions and
a final extension at 72uC for 15 min. The relative gene expression
level was calculated by the comparative Ct method (i.e. 2
2DCt
method), and expressed as 2‘-([delta]Ct, sample–[delta]Ct,ref ).
Measurements of Cyclic Adenosine 39,59-
monophosphate
CTR down-stream signaling was quantified by cyclic adenosine
39,59-monophosphate (cAMP) levels. FDC explants were incubated
withorwithout20 ng/mLT3for0,4and8days.Thentheexplants
were incubated with 100 mM of the phosphodiesterase inhibitor 3-
isobutyl-1-methylxanthine(IBMX)for2hoursandnexttreatedwith
either 10 nM salmon calcitonin or 10 nM human calcitonin, or
100 mMforskolin(asapositivecontrol).ExplantstreatedwithIBMX
alone served as background controls. All compounds were obtained
from Sigma-Aldrich, UK. After treatment, the explants were lysed
using a 3.5 U/mL papain solution for 24 hours at 60uC. Measure-
ment of cAMP was performed using the HTRFH cAMP cell-based
assay (CisbioBioassays, US).
Statistics
Statistical analyses were performed using one-way ANOVA
analysis with Dunnett’s post-test or Student’s t test. Differences
between mean values were considered as statistically significant if
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(different cows), whereas n represents number of explants
(replicates) in each experiment. Expression data are shown as
mean with 95% confidence interval (CI). Biomarker results are
shown as geometric mean with 95% confidence interval (CI).
Results
Expression of Prehypertrophic Markers and the CTR in T3-
induced Cartilage Explants
It has previously been shown that T3 induces early chondrocyte
hypertrophy [43]. These data was confirmed in a single experi-
ment in current study. T3 administered at 20 ng/mL to cartilage
explants over four days did not change the viability of
chondrocytes, as measured by Alamar blue (data not shown). T3
induced a prehypertrophic morphological phenotype in the deep
zone of the cartilage compared to control (w/o) (fig. 1A, B). No
notable changes were observed in the upper zone of the cartilage
(data not shown). The size of the lacunas was measured giving the
perimeter. It was found that there was a clear separation between
w/o and T3-induced explants (fig. 1C).
The mRNA expression of early hypertrophic markers was
investigated. Compared with control (w/o, explants not subjected
to T3), ALP expression was significantly increased after T3
induction (table 2). MMP13 and IHH were likewise significantly
increased in the T3-induced cartilage explants (table 2). COL10A1
expression was also increased, however not significantly (table 2).
CALCR expression was significantly increased in T3-induced
explants compared to controls (table 2).
Immunolocalization of the CTR in T3-induced Explants
The membrane expression of the CTR was investigated by
immunohistochemistry after four days of T3 and sCT co-
stimulation. The CTR was expressed by many cells in the upper
and mid cartilage zone, and there seemed to be no notable
difference between the w/o and T3-induced explants when
looking at the upper and middle zone (fig. 2). In a semi-
quantitative assessment it was found that 34–54% of the cells in
the upper zone of the control explants and 53%–64% in the T3-
Table 1. List of primer sequences applied in quantitative PCR analysis.
Gene Forward Reverse Description
COL X
NM_000493/ X73320
59CTGAGCGATACCAAACACCTAC’3 59GGATGCCTTGCTCTCCTC’3 Marker of hypertrophy
ALP
NM_176858
59TGCGACTGACCCTTCACTCTC’3 59CACCAGCAGGAAGAAGCCTTT’3 Marker of calcification
IHH
NM_001076870
59ATCTCGGTGATGAACCAGTG’3 59CCTTCGTAATGCAGCGACT’3 Marker of differentiation and pre-hypertrophy
MMP13
NM_174389
59ACATCCCAAAACGCCAGACAA’3 59GATGCAGCCGCCAGAAGAAT’3 Marker of chondrocyte activation and
differentiation
CTR
NM_001076269
59GGCTGCCAAAGGGTAAC’3 59AAATCTTGCAGCTCACCG’3
GAPDH
NM_001034034
59CCTGGAGAAACCTGCCAAGTAT’3 59AATGAGCTTGACAAAGTGGTCGTT’3 House holding gene
doi:10.1371/journal.pone.0040081.t001
Figure 1. The effect of T3 stimulation on chondrocyte morphology in articular cartilage explants after 4 days of T3 administration.
A) Control section (w/o) (n=2). B) T3-induced explant (n=4). C) Measurement of the perimeter in cells of the deep zone.
doi:10.1371/journal.pone.0040081.g001
Table 2. Fold expression (mean(95%CI)) of pre-hypertrophic
markers and the CTR in T3-induced explants compared with
control (w/o).
w/o T3 P N n (w/o, T3)
ALP 1.38 (0.75–2.52) 26.2 (5.2–132.2) 0.0011 4 10, 14
IHH 1.53 (0.69–3.46) 4.29 (1.48–12.5) 0.021 3 8, 10
COL10A1 1.44 (0.45–4.55) 3.32 (0.93–11.8) Ns 3 8, 10
MMP13 1.43 (0.74–2.77) 7.61 (5.03–11.5) 0.0002 4 10, 14
CALCR 1.87 (0.96–3.64) 12.3 (6.93–21.8) 0.0003 2 6, 6
doi:10.1371/journal.pone.0040081.t002
Effect of Salmon Calcitonin on Cartilage
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e40081induced explants were positive for the CTR (N=2). The CTR was
expressed in the middle zone by 24–57% in the controls and 33–
63% in the T3-induced (N=2). And in the deep zone 45–67% of
the cells in the controls and 66–67% of the cells in the T3-induced
explants were positive for the CTR (N=2) (fig. 2). Although
immunoreactivity was observed in both w/o and T3-induced
explants, there was a tendency toward more intense staining in the
T3-induced explants (fig. 2); however this is subjective observation.
Co-stimulated with 1 nM and 10 nM sCT reduced the number of
positive cells to less than 43% in the deep layer of the explants
(fig. 2).
Cellular and Extracellular Effects of Salmon Calcitonin on
T3-induced Explants
It was investigated next whether co-stimulation with T3 and
salmon calcitonin (sCT) could change the expression pattern of the
chondrocytes as observed by immunohistochemistry. Compared
with T3-induced explants, ALP was significantly decreased in
response to 1 nM sCT, (table 3). IHH was significantly decreased
in response to 1 nM sCT (table 3). There was a tendency towards
decreased COL10A expression, but the difference was not
significant (table 3). MMP13 expression was significantly de-
creased in response to 10 nM (table 3).
Subsequently, sCT’s anabolic and catabolic effects on cartilage
were investigated. Co-stimulation with salmon calcitonin did not
change the degree of cell viability measured by Alamar blue in
explants treated with T3 alone (fig. 3A). The ALP activity was
reduced to the level of the control W/O (fig. 3B). No significant
differences in type II collagen turnover measured by C2M and
P2NP (fig. 3C and 3D) were observed in the explants treated with
salmon calcitonin and the control samples. In contrast, aggrecan
degradation was significantly inhibited by both doses of sCT
(fig. 3E).
Induction of Cyclic AMP in T3-induced Explants
Cartilage explants were preincubated with the nonselective
phosphodiesterase inhibitor IBMX to retain the cAMP concen-
tration upon induction of the CTR receptor. Induction of CTR,
measured by cAMP, was increased in the T3-induced explants
treated with 10 nM sCT compared with the control (fig. 4A). The
effect was even higher when the explants were stimulated with T3
for 8 days (fig. 4A). To investigate whether the effect was related to
the CTR alone or in conjunction with receptor activity modifying
proteins (RAMPs), equal amounts of human calcitonin, which is
known not to activate CTR in the presence of RAMPS, were
applied to the explants. Human calcitonin [10 nM] did not have
the same effect as salmon calcitonin on increasing cAMP release
(fig. 4A).
Discussion
This study investigated the presence and function of the CTR in
T3-induced bovine articular cartilage explants. First of all, we
confirmed that T3 could induce early hypertrophy of the
chondrocytes in the explants: expression of hypertrophic markers
was increased and chondrocyte enlargement (pre-hypertrophy)
and proliferation was observed, compared with untreated controls.
Furthermore, an elevation in MMP activity measured by release of
degradation fragments of type II collagen and aggrecan was
observed. Interestingly, these T3-induced chondrocytes had an
elevated expression of the CTR, which suggests that CTR
expression is associated to early chondrocyte hypertrophy. This
Figure 2. Immunolocalization of the calcitonin receptor (CTR) in cartilage explants induced with or without T3 for 4 days. First panel
shows the superficial layer of the cartilage, second panel the mid layer of the cartilage and the third panel the deep layer of the cartilage. Treatment
scheme is indicated at the top of the pictures. The pictures are representative of 3 replicates from the same experiment. Positive staining is visualized
by brown color.
doi:10.1371/journal.pone.0040081.g002
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the chondrocytes. Different phenotypes of chondrocytes stained
positive for the CTR. There was a tendency toward more intense
staining in the T3 induced explants compared to controls. This
was most pronounced in the deep layer of the explants were the
morphological shift was more evident. However, a more thorough
investigation needs to be conducted to quantify the extent of the
immune-localization and the difference induced by T3. Notably,
T3-induced explants treated with salmon calcitonin seemed to
present less CTR, which was expected, since the receptor is
internalized as a consequence of sCT binding [44;11]. This was
further supported by an elevated cAMP release upon treatment
with salmon calcitonin from T3-induced cartilage explants
compared to controls. Human calcitonin, however, did not have
the same effect of raising cAMP levels, which could indicate that
the response is dependent on RAMPs (e.g. the amylin receptor).
The exact receptor subtype needs to be confirmed in more detail
in another experimental set-up. Moreover, when co-stimulating
the explants with the most potent concentrations of salmon
calcitonin [24], the cartilage appeared to be protected from
hypertrophy. Compared with explants treated with T3 alone, the
expression of the hypertrophic markers was reduced in the co-
stimulated explants and aggrecan degradation was prevented. In
summary, we showed that T3-induced chondrocytes expressed the
CTR and that induction of the receptor seemed to protect the
cartilage from hypertrophy. These are the first data to show
a direct connection between early chondrocyte hypertrophy in
cartilage explants and the potentially protective effect of the CTR.
The effects of calcitonin on bone have been demonstrated
previously to be mediated by direct binding of the hormone to
CTRs expressed in osteoclasts in their basolateral membrane [45].
In contrast, no conclusive evidence on the expression of the CTR
in cartilage has been provided. Our group previously reported the
existence of an intron spanning sequence of the coding region of
CTR mRNA, as well as the full-length transcript, in human
articular cartilage [13;19]. Furthermore, we showed that the
receptor on the chondrocytes’ surface was a functional receptor
[14]. In contrast, Lin and colleagues concluded that the CTR was
not expressed in human cartilage after investigating its existence in
tissue and isolated chondrocytes by PCR, western blotting and
immunochemical analysis [15]. Nevertheless, the CTR was
identified and found to be functional in osteocytes [46], adding
to the growing evidence that CTR is expressed in cells of the
mesenchymal lineage as chondrocytes.
Table 3. Fold expression (mean(95%CI)) of pre-hypertrophic marker in response to 1 and 10 nM sCT stimulation of T3-induced
explants compared with T3-induced alone (T3).
T3 T3+1 nM sCT T3+10 nM sCT W/O
ALP (N=3, n=9) 38.0 (15.8–91.5) 6.67 (2.96–15.0) 20.6 (5.84–72.3) 1.54 (0.85–2.77)
0.0001
1 ,0.05
# ns ,0.001
#
IHH (N=3, n=9) 3.32 (2.04–5.40) 1.47 (0.62–3.67) 2.64 (1.65–4.22) 1.37 (0.76–2.47)
0.021
1 ,0.05
# ns ,0.05
#
COL10A1 (N=3, n=9) 2.03 (0.91–4.53) 0.58 (0.13–2.63) 2.03 (1.15–3.59) 1.43 (0.76–2.68)
ns ns ns ns
MMP13 (N=3, n=9) 6.26 (4.21–8.31) 3.39 (1.21–9.42) 1.90 (1.04–3.48) 1.42 (0.93–2.16)
0.0002
1 ns ,0.01
# ,0.001
#
1P-value of ANOVA test,
#P-value of Dunnett’s post-test.
doi:10.1371/journal.pone.0040081.t003
Figure 3. The effect of co-stimulation with salmon calcitonin (sCT) on cartilage turnover. A) Cell viability, measured by Alamar blue, of the
cartilage explants. B) Induction of alkaline phosphatase (ALP) activity in the conditioned medium. C) Measurement of matrix metalloproteinase
(MMP)-derived type II collagen degradation fragments (C2M) released to the conditioned medium. D) Measurement of type II procollagen (P2NP)
released to the conditioned medium. E) Measurement of MMP-derived aggrecan collagen degradation fragments (AGNx-II) released to the
conditioned medium. Comparisons were performed by one-way ANOVA with Dunnetts post test. Significance levels; *p,0.05 and **p,0.01, data
shown as mean with CI-95% n=6.
doi:10.1371/journal.pone.0040081.g003
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expressed by chondrocytes [46]. An important contributor to this
debate has been the use of different in vitro systems. There is
evidence that culturing chondrocytes as an adherent monolayer
invariably leads to a process of differentiation whereby cells adopt
a fibroblastic morphology, lose their chondrocyte-specific gene-
expression pattern and initiate or upregulate the expression of
fibroblast-associated genes such as type I, III and V collagens and
versican [47;48;49]. Therefore, chondrocytes differentiated on
plastic with fetal bovine serum cannot be used as a representative
sample of cartilage cell biology, particularly in regards to cartilage
gene expression profile. It is more meaningful to study chon-
drocytes in their native micro-environment – the cartilage matrix.
The cartilage matrix is a compact, collagenous and hypoxic entity,
which depends on diffusion for nutrients. The cartilage seems to be
rather protective of the chondrocytes, protecting them from
differentiation and exogenous factors [50]. Joint degenerative
diseases are partly characterized by loss of structural integrity and
degradation of the cartilage, leading to the loosening and exposure
of the chondrocyte to its surroundings. This results in the initiation
of a pathway of cellular differentiation and hypertrophy [1].
Targeting cartilage for drug development should include in-
vestigation of the relevant chondrocyte phenotypes. The explant
model presented here might be a good in vitro model for
investigating the mode of action of candidate drugs on articular
cartilage.
The present study clearly demonstrates that the CTR is more
highly expressed in hypertrophic than normal chondrocytes, and
that early hypertrophic chondrocytes respond to salmon calcito-
nin. Interestingly, human calcitonin did not affect the chondro-
cytes. Because human calcitonin only activates the CTR in the
absence of RAMPs [51], our findings suggest that RAMPs must
have been present, together with the CTR, in the explants
respongding to salmon calcitonin.
In conclusion, the investigation of pharmacological interven-
tions for OA should focus on the correct phenotype of
chondrocytes. In the present study we clearly demonstrated that
hypertrophic chondrocytes have a different phenotype than
normal chondrocytes, they express more of the CTR, and they
respond to salmon calcitonin.
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